spacer
home > ebr > winter 2002 > cell-based high-throughput screens for drug discovery
PUBLICATIONS
European Biopharmaceutical Review

Cell-Based High-Throughput Screens for Drug Discovery

The rapid progress in elucidating the mechanisms underlying human diseases, along with the enormous amount of data generated by the Human Genome Project, are significantly increasing the number of proteins that can be targeted for potential drug treatment. Parallel to these developments, the number and diversity of compounds that can be tested for activity against these targets are also rapidly expanding.

The combination of these trends in biology and chemistry has spurred the development of increasingly rapid, selective and reliable high-throughput screening assays to be applied in the early phase of drug discovery Typically, such assays allow screening of large numbers of compounds in an automated fashion to identify those that show an activity, either as agonists or as antagonists, on a defined biological target. Most of the assay formats developed to date can be grouped into cell-free (biochemical) or cell-based (cellular) assays. This article describes the applicability of cell-based assays in the early phase of drug discovery, with a particular focus on the use of yeast cells as an attractive option for high-throughput screens.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Alcide Barberis, Chief Scientific Officer of ESBATech AG Dr Alcide Barberis is the Scientific Founder of ESBATech, a drug discovery company specialising in cell-based functional screening assays and high-throughput compound screens. Dr Barberis received his PhD in Molecular Biology and Biochemistry from the University of Zurich in 1988. He later moved to Harvard University as a postdoctoral fellow, where he began working with yeast as a model system to study the fundamental mechanisms of gene regulation.
After a period at the Research Institute San Raffaele in Milan, he became group leader at the Institute of Molecular Biology at the University of Zurich. In 2002 he left academic research to become full-time Chief Scientific Officer of ESBATech.

spacer
Dr Alcide Barberis
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Wool packaging firm’s green scheme goes ‘beyond recycling’

An award-winning company that has spent more than 10 years innovating in sustainable packaging has launched a scheme that it says goes ‘beyond recycling’ – by allowing the end user to return their packaging directly to them to be used again.
More info >>

White Papers

Blockbuster Drugs Need Blockbuster Components

West Pharmaceutical Services, Inc.

Many of the world’s blockbuster drugs are now delivered via a prefilled syringe system or auto-injector. To ensure patient safety, pharmaceutical manufacturers need high-quality components that feature reduced particulates and ensure consistency of delivery while fitting the changing needs of higher-volume delivery systems.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement